Treatment Tied to Survival Benefit in Complex Bladder Cancer

Medically complex patients with superficial disease have reduced deaths with treatment vs. observation.
Medically complex patients with superficial disease have reduced deaths with treatment vs. observation.

HealthDay News — Cancer treatment is associated with a clinically meaningful survival benefit in older, medically complex patients with superficial bladder cancer (SBC), according to a study published online October 5 in Cancer.

Tullika Garg, MD, MPH, from Geisinger in Danville, Pennsylvania, and colleagues evaluated the association between treatment of SBC and 10-year mortality in 1800 medically complex patients aged ≥60 years. 

Related Articles

Overall, 1485 patients (82.5%) received treatment and 315 patients (17.5%) underwent observation. The researchers found that treatment was associated with a 30% reduction in death, while having multiple complex conditions (MCC) was associated with a 72% increase in death in unweighted multivariable analysis. There was also a survival benefit for treatment in weighted analysis with adjustment (adjusted hazard ratio, 0.66).

"These data provide a foundation for future work aimed at personalizing the treatment guidance of older patients with cancer with MCC," the authors write.

Abstract/Full Text (subscription or payment may be required)